Q&A: Oncologist and health economist Dr. Gary Lyman discusses a class of treatments on the rise. Will prices follow?
May 31, 2018
| By Diane Mapes / Fred Hutch News Service
Costly biologics and their "generic-ish" counterparts, biosimilars, are about to step into the pharmaceutical spotlight in a big way. We sat down with Fred Hutch's Dr. Gary Lyman, an oncologist and national thought leader on health economics, to learn more about burgeoning biopharmaceuticals.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.